Overcoming metastatic melanoma with BRAF inhibitors

被引：0
作者：
Seunghee Hong
Sungwoo Hong
机构：
[1] Korea Advanced Institute of Science and Technology (KAIST),Department of Chemistry
来源：
Archives of Pharmacal Research | 2011年 / 34卷
关键词：
Melanoma; Brain Metastasis; Chronic Myeloid Leukemia; Metastatic Melanoma; BRAF Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Melanoma has the capacity to spread via the blood stream to the brain, and has been notoriously resistant to drug therapy. An activating mutation in the gene encoding BRAF is known to be responsible for half of melanomas. This article provides a review of GSK2118436 and PLX4032 as potential therapeutics for the treatment of melanomas by inhibiting oncogenic BRAF.
引用
收藏
页码：699 / 701
页数：2
相关论文
共 187 条
[1]  
Arkenau H. T.(2011)Targeting BRAF for patients with melanoma Br. J. Cancer 104 392-398
[2]  
Kefford R.(2010)Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 596-599
[3]  
Long G. V.(2010)Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 363 809-819
[4]  
Bollag G.(2010)COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 968-972
[5]  
Hirth P.(2006)Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 Cancer Res. 66 11100-11105
[6]  
Tsai J.(2010)Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation Nature 468 973-977
[7]  
Zhang J.(2008)Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U. S. A. 105 3041-3046
[8]  
Ibrahim P. N.(2010)RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res. 70 5518-5527
[9]  
Cho H.(undefined)undefined undefined undefined undefined-undefined
[10]  
Spevak W.(undefined)undefined undefined undefined undefined-undefined
12345678910